Results 11 to 20 of about 4,961 (248)

Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet-α, protamine). [PDF]

Br J Clin Pharmacol
Bleeding events are common in patients prescribed anticoagulants and can have devastating consequences. Several specific and nonspecific agents have been developed to reverse the effects of anticoagulant drugs or toxins. Vitamin K, as the oldest of these
Bekka E, Liakoni E.
europepmc   +6 more sources

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis [PDF]

The Journal of Emergency Medicine, 2017
Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran.We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be able to reverse the anticoagulant effect of dabigatran in patients who had uncontrolled bleeding (group A) or were about to ...
Charles V. Pollack, Paul Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, CW Kam, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Gordon Royle, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Peter Verhamme, Bushi Wang, Laura Young, Jeffrey I. Weitz   +20 more
semanticscholar   +12 more sources

Idarucizumab for Dabigatran Reversal [PDF]

New England Journal of Medicine, 2015
BACKGROUND Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.
Charles V. Pollack, Paul Reilly, John W. Eikelboom, Stephan Glund, Peter Verhamme, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Bushi Wang, CW Kam, Jeffrey I. Weitz   +17 more
semanticscholar   +6 more sources

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy [PDF]

Medicina, 2022
Background and Objectives: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular ...
Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis   +3 more
doaj   +4 more sources

Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage [PDF]

Clinical Practice and Cases in Emergency Medicine, 2017
Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Jonathan Balakumar, Ruben Santiago, Mark Supino   +2 more
doaj   +6 more sources

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report [PDF]

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +4 more sources

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj   +2 more sources

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals [PDF]

Research and Practice in Thrombosis and Haemostasis, 2021
Background Idarucizumab, a monoclonal antibody fragment that reverses the anticoagulant effect of dabigatran, was approved for use in Canada in 2016. Objective Our objective was to assess the safety of idarucizumab among patients who received the drug ...
Jameel Abdulrehman, Sahar Zarabi, Carolyne Elbaz, Kerstin deWit, Yulia Lin, Michelle Sholzberg, Rita Selby   +6 more
doaj   +2 more sources

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting [PDF]

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +2 more sources

Perioperative Myocardial Infarction Following Dabigatran Reversal With Idarucizumab in a Patient Undergoing Orthotopic Liver Transplantation. [PDF]

Cureus, 2023
Insufficient information is available regarding the administration of anticoagulants, specifically direct oral anticoagulants, in individuals with cirrhosis awaiting liver transplantation.
Barroso A, Martinez-Gonzalez MC, Knowlson N, Miguel AM, Perez G.   +4 more
europepmc   +2 more sources